Illumina launches genomics incubator in China
Illumina has partnered with investment firm Sequoia Capital China to launch a new collaboration designed to create an incubator for startup companies in the life sciences that have a focus on genomics. Read More
Novavax to produce Canadian supply of COVID-19 vaccine in Canada
Novavax has signed a memorandum of understanding with the Canadian government to produce the company's protein-based COVID-19 vaccine candidate, NVX-CoV2373, in Canada. Read More
Adverum publishes long-term safety data of gene therapy candidate
Adverum Biotechnologies has published preclinical data on its intravitreal gene therapy candidate ADVM-022 in Translational Vision Science & Technology. Read More
FDA accepts VBI's hepatitis B vaccine BLA
The U.S. Food and Drug Administration (FDA) has accepted the biologics license application (BLA) submitted by VBI Vaccines for its 3-antigen prophylactic hepatitis B vaccine candidate for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults. Read More
Dynavax helps advance COVID-19 vaccine candidates
Dynavax Technologies said it will be providing additional quantities of its CpG 1018 adjuvant for Valneva's SARS-CoV-2 vaccine candidate and has also signed a deal to supply CpG 1018 to the Coalition for Epidemic Preparedness. Read More
Invicro touts research, launches TauIQ software
Konica Minolta subsidiary Invicro is directing attention to new research results from its TauIQ software for quantitative analysis of tau positron emission tomography biomarker data in Alzheimer's disease clinical trials. The company has also launched the software as a product. Read More
Gilead partners with Gritstone for HIV vaccine, increases investment in Arcus
Gilead Sciences said it's collaborating with Gritstone Oncology to develop a vaccine-based immunotherapy aimed at providing a curative treatment for HIV. In addition, the company has also increased its stake in Arcus Biosciences. Read More
Horizon to acquire Viela Bio
Horizon Therapeutics has entered into an agreement to acquire Viela Bio for $53 per share in cash in a deal worth about $3.05 billion. The transaction is expected to close by the end of the first quarter of 2021. Read More
Exelixis, Adagene partner on masked ADCs
Exelixis and Adagene have signed a license agreement to generate masked versions of monoclonal antibodies from Exelixis' preclinical pipeline for the development of antibody-drug conjugates (ADCs) or other biologics against Exelixis-nominated targets. Read More
Cytiva acquires Vanrx Pharmasystems
Cytiva has acquired Vanrx Pharmasystems, a Canadian-based company that makes robotic aseptic filling machines to fill vials, syringes, and cartridges. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
